DE69326064T2 - Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten - Google Patents

Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten

Info

Publication number
DE69326064T2
DE69326064T2 DE69326064T DE69326064T DE69326064T2 DE 69326064 T2 DE69326064 T2 DE 69326064T2 DE 69326064 T DE69326064 T DE 69326064T DE 69326064 T DE69326064 T DE 69326064T DE 69326064 T2 DE69326064 T2 DE 69326064T2
Authority
DE
Germany
Prior art keywords
human
protein
pct
lymphocytes
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69326064T
Other languages
English (en)
Other versions
DE69326064D1 (de
Inventor
Cornelis Melief
Wybe Kast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEED CAPITAL INVESTMENTS
Universiteit Leiden
Original Assignee
SEED CAPITAL INVESTMENTS
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SEED CAPITAL INVESTMENTS, Universiteit Leiden filed Critical SEED CAPITAL INVESTMENTS
Application granted granted Critical
Publication of DE69326064D1 publication Critical patent/DE69326064D1/de
Publication of DE69326064T2 publication Critical patent/DE69326064T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69326064T 1992-05-26 1993-05-18 Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten Expired - Fee Related DE69326064T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92201510 1992-05-26
PCT/NL1993/000102 WO1993024525A1 (en) 1992-05-26 1993-05-18 PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES

Publications (2)

Publication Number Publication Date
DE69326064D1 DE69326064D1 (de) 1999-09-23
DE69326064T2 true DE69326064T2 (de) 2000-05-25

Family

ID=8210629

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326064T Expired - Fee Related DE69326064T2 (de) 1992-05-26 1993-05-18 Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten

Country Status (11)

Country Link
US (1) US5679641A (de)
EP (1) EP0643726B1 (de)
JP (2) JPH08501280A (de)
AT (1) ATE183514T1 (de)
AU (1) AU681853B2 (de)
CA (1) CA2136624A1 (de)
DE (1) DE69326064T2 (de)
DK (1) DK0643726T3 (de)
ES (1) ES2139012T3 (de)
GR (1) GR3031919T3 (de)
WO (1) WO1993024525A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261314T1 (de) * 1992-07-22 2004-03-15 Univ Princeton P53 impfstoff
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
AU7478394A (en) * 1993-08-06 1995-02-28 Cytel Corporation Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
CA2207736A1 (en) 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US5925799A (en) * 1996-03-12 1999-07-20 Abb Lummus Global Inc. Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
NZ331688A (en) * 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) * 1998-05-14 1998-05-14 Karolinska Innovations Ab Inhibition of p53 function by a p53-derived peptide
CA2330824A1 (en) * 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
EP1165144A2 (de) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Mit einem eigengen-wildtyp transduzierte dendritische zellen lösen starke antitumor immunantwort aus
TW410377B (en) * 1999-06-17 2000-11-01 Taiwan Semiconductor Mfg Method of planarization and the apparatus of the same
DE60030450T2 (de) * 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001041788A1 (en) * 1999-12-10 2001-06-14 Epimmune, Inc. INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
CN101712721A (zh) * 2000-06-05 2010-05-26 阿尔托生物科学有限公司 T细胞受体融合物及共轭物以及其使用方法
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
CN1692124B (zh) 2001-06-05 2012-05-30 阿尔特生物科学公司 与p53结合的T细胞受体分子以及其用途
US7179784B2 (en) * 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
JP5068931B2 (ja) * 2002-07-12 2012-11-07 ザ ジョンズ ホプキンス ユニバーシティー 独自のクローン形質のリンパ球受容体に結合する試薬および方法
EP1888105A2 (de) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53-impfstoffe zur krebsbehandlung
EP1933864A4 (de) * 2005-09-07 2009-12-16 Receptor Logic Ltd Antikörper als t-zell-rezeptor-mimics, herstellungsverfahren und ihre verwendungen
WO2008021160A2 (en) * 2006-08-17 2008-02-21 Trustees Of Boston University Regulation of litaf modulated cytokine production by a novel p53 short peptide
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
KR20200065026A (ko) * 2017-09-29 2020-06-08 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN114651001A (zh) * 2019-11-07 2022-06-21 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

Also Published As

Publication number Publication date
ES2139012T3 (es) 2000-02-01
ATE183514T1 (de) 1999-09-15
AU681853B2 (en) 1997-09-11
WO1993024525A1 (en) 1993-12-09
JP2004123708A (ja) 2004-04-22
GR3031919T3 (en) 2000-03-31
DE69326064D1 (de) 1999-09-23
EP0643726A1 (de) 1995-03-22
EP0643726B1 (de) 1999-08-18
CA2136624A1 (en) 1993-12-09
US5679641A (en) 1997-10-21
JPH08501280A (ja) 1996-02-13
DK0643726T3 (da) 2000-03-20
AU4359193A (en) 1993-12-30

Similar Documents

Publication Publication Date Title
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
IL105554A0 (en) Peptides of human papilloma virus for use in human t cell response inducing compositions
DE68925226D1 (de) Monoklonale Antikörper
ATE255126T1 (de) Unterdrückung von immunantwort durch hemmung von cathepsin s
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
ATE25984T1 (de) Pharmakologisch aktive peptide.
BG101846A (en) HUMAN DNase I VARIANTS
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
MX9700199A (es) Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes.
BG101847A (en) Human dnase i variants

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee